Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...
Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...
of 85% from THIO and Libtayo. Vlad Vitoc, CEO of MAIA, said: “Treatment with THIO now shows a 99% probability that OS will extend past chemotherapy’s measure by a wide margin. “THIO’s ...
Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with ...
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...
THIO sequenced with Libtayo extended overall survival in those with non ... OS compared with the five-to-six-month OS that has been observed with standard-of-care chemotherapy treatments in NSCLC in a ...
The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...
Amarnath Challapalli, MBBS, MD, MRCP, FRCR, PhD, discusses some of the most promising findings from the EPIC-A trial of cemiplimab with chemotherapy in treating locally advanced or metastatic penile ...
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab ... on or after platinum-based chemotherapy, irrespective of PD-L1 expression ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback